- Home
- BCAT vs BCRX Comparison
BCAT vs BCRX Comparison
Compare BCAT & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- BCRX
- Stock Information
- Founded
- BCAT 2020
- BCRX 1986
- Country
- BCAT United States
- BCRX United States
- Employees
- BCAT N/A
- BCRX N/A
- Industry
- BCAT Finance/Investors Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAT Finance
- BCRX Health Care
- Exchange
- BCAT Nasdaq
- BCRX Nasdaq
- Market Cap
- BCAT 1.8B
- BCRX 1.5B
- IPO Year
- BCAT N/A
- BCRX 1994
- Fundamental
- Price
- BCAT $15.67
- BCRX $7.45
- Analyst Decision
- BCAT
- BCRX Buy
- Analyst Count
- BCAT 0
- BCRX 6
- Target Price
- BCAT N/A
- BCRX $15.17
- AVG Volume (30 Days)
- BCAT 308.8K
- BCRX 2.3M
- Earning Date
- BCAT 01-01-0001
- BCRX 02-24-2025
- Dividend Yield
- BCAT 9.38%
- BCRX N/A
- EPS Growth
- BCAT N/A
- BCRX N/A
- EPS
- BCAT 1.43
- BCRX N/A
- Revenue
- BCAT N/A
- BCRX $412,579,000.00
- Revenue This Year
- BCAT N/A
- BCRX $38.01
- Revenue Next Year
- BCAT N/A
- BCRX $19.04
- P/E Ratio
- BCAT $11.41
- BCRX N/A
- Revenue Growth
- BCAT N/A
- BCRX 29.92
- 52 Week Low
- BCAT $13.67
- BCRX $4.03
- 52 Week High
- BCAT $16.38
- BCRX $8.88
- Technical
- Relative Strength Index (RSI)
- BCAT 51.73
- BCRX 47.51
- Support Level
- BCAT $15.40
- BCRX $7.53
- Resistance Level
- BCAT $15.76
- BCRX $8.02
- Average True Range (ATR)
- BCAT 0.22
- BCRX 0.44
- MACD
- BCAT 0.06
- BCRX -0.06
- Stochastic Oscillator
- BCAT 81.58
- BCRX 32.03
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.